ECTRIMS Insights
Shedding new light on the pathogenesis of MS
The underlying pathogenesis of MS remains an area of considerable interest and research and was ...read more
Can biomarkers help us move towards a more holistic approach to tackling MS?
The development and validation of biomarkers is essential to furthering our understanding of disease progression ...read more
ECTRIMS 2022 and the Evolution of the Treatment Arena for MS
As our knowledge and understanding of the underlying pathogenesis of MS increases, so the treatment ...read more